Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 3(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02811315Withdrawn

Flutiform in Treatment of Patients With Asthma in Daily Clinical Practice.

Role: lead

NCT01376401Phase 2Completed

Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma

Role: collaborator

NCT01167127Phase 3Completed

Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain

Role: lead

NCT01167699Phase 3Completed

Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain

Role: lead

All 4 trials loaded